Edition:
United Kingdom

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

18.75USD
16 Aug 2018
Change (% chg)

-- (--)
Prev Close
$18.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
154,649
52-wk High
$19.60
52-wk Low
$8.07

Chart for

About

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab... (more)

Overall

Beta: --
Market Cap(Mil.): $695.75
Shares Outstanding(Mil.): 51.35
Dividend: --
Yield (%): --

Financials

  CHRS.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -2.70 -- --
ROI: -86.92 1.78 14.61
ROE: -- 3.28 16.33

BRIEF-Coherus Prices Public Offering Of Common Stock

* SAYS PUBLIC OFFERING OF 5.17 MILLION COMMON SHARES PRICED AT $14.50PER SHARE Source text for Eikon: Further company coverage:

23 May 2018

BRIEF-Coherus Announces Proposed Public Offering Of Common Stock

* COHERUS BIOSCIENCES INC SAYS COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $75,000,000 OF SHARES OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

21 May 2018

BRIEF-Coherus BioSciences Re-Submits Biologics License Application For CHS-1701

* COHERUS BIOSCIENCES RE-SUBMITS BIOLOGICS LICENSE APPLICATION FOR CHS-1701 (PEGFILGRASTIM BIOSIMILAR CANDIDATE)

03 May 2018

BRIEF-Coherus Biosciences Says U.S. Court Grants Motion To Dismiss Patent Infringement Complaint

* COHERUS BIOSCIENCES-U.S. COURT ADOPTED MAGISTRATE JUDGE BURKE'S REPORT & RECOMMENDATION TO GRANT MOTION OF CO TO DISMISS PATENT INFRINGEMENT COMPLAINT

26 Mar 2018

BRIEF-Coherus BioSciences Reports Q4 Loss Per Share $0.84

* COHERUS BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

08 Mar 2018

Competitors

Earnings vs. Estimates